Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Zhuhai Beihai Biotech Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, so the docket is distributed across separate examination assignments.
WELLS, LAUREN QUINLAN is the busiest examiner, with 1 pending matter. Each action warrants its own examiner-focused response while remaining aligned with the portfolio's broader claim objectives.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044309 | FORMULATIONS OF CABAZITAXEL | CRAIG, KAILA ANGELIQUE | 41d |
| 18839035 | DOCETAXEL COMPOSITIONS AND METHODS | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839035 | DOCETAXEL COMPOSITIONS AND METHODS | WELLS, LAUREN QUINLAN | 1622 | §102§103DP | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18044309 | FORMULATIONS OF CABAZITAXEL | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Final Rejection | 41d | Pending | Mar 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhuhai Beihai Biotech Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Lauren Quinlan Wells has the most, with 1 of Zhuhai Beihai Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
